RecruitingPhase 2/3

Caffeine Kinetics and CrossFit®-Specific Performance

Poland25 participantsStarted 2022-06-29

Plain-language summary

The study aims at assessing the relation between caffeine (CAF) and paraxanthine (PAX) kinetics after acute ingestion of caffeine (3 mg/kg body mass) in the form or mono- or multi-ingredient preparations and CrossFit®-specific performance or selected indicators of psychophysiological state. Blood indicators of muscle damage/recovery, acid-base balance and electrolytes levels will be evaluated. The impact of genetic variations in the polymorphisms rs5751876 in ADORA2A gene and rs762551 in CYP1A2 on CAF/PAX kinetics will be considered.

Who can participate

Age range18 Years – 40 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * written informed consent from all participants before the study, * a current medical clearance to practice sports, * training experience any sport discipline ≥ 5 years and training experience in HIFT ≥ 2 years, * performing ≥3 training units per week, * participating in CrossFit® competitions at least once a year. Exclusion Criteria: * current injury, * any health-related contraindication, * declared general feeling of being unwell, * unwilling to follow the study protocol, * serious disease or metabolic problems, * smoking and tobacco use, * presence of infectious disease in the previous 4 weeks of the study.

What they're measuring

The effect of acute ingestion of the same dose of caffeine (3 mg/kg BM) in form of 3 different preparations on discipline-specific performance

Timeframe: 60 minutes after ingestion of tested supplements/placebo

Trial details

NCT IDNCT05516212

SponsorPoznan University of Physical Education

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-07-29

Contact for this trial

Krzysztof Durkalec-Michalski, Prof., PhD

+48 (61) 835 51 65 durkalec-michalski@awf.poznan.pl